---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000036"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T13:22:02.093019+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued

## Summary
- GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).
- VITAS net patient revenue $350M (+13.6%), ADC 19,352 (+11%), adjusted EBITDA excl. Medicare Cap $83.3M (+61.6%), margin 23.7%.
- Roto-Rooter revenue $235.9M (-1.1%), adjusted EBITDA $64.9M (-6.4%), margin 27.5% (down 154 bps).
- FY2024 adj. EPS guidance $23.30-$23.70 vs 2023 adj. EPS $20.30; VITAS rev growth 9-9.8%, Roto-Rooter rev growth 3.5-4%.
- Cash $264M, no debt; repurchased 79,512 shares for $46M at $579.09 per share.

## SEC filing metadata
- accession: 0001562762-24-000036
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/0001562762-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/che-20240227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000036
- JSON: https://secwatch.observer/filing/0001562762-24-000036.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000036.txt

## Key facts
- Earnings Releases
  CHEMED CORP reported the quarter ended December 31, 2023 results: revenue $585.9 million, EPS $5.90.
  - Period: the quarter ended December 31, 2023
  - Revenue: $585.9 million
  - EPS: $5.90
  - Result: reported results
  source text: Retention Program was $19.6 million and $14.6 million, respectively.  Results for Quarter Ended December 31, 2023  Consolidated operating results: · Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Diluted EPS of $6.60, an increase of 35.0%  VITAS segment operating results: · Net Patient
  evidence_url: https://www.sec.gov/Archives/edgar/data/19584/000156276224000036/0001562762-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.